Publication:
Dynamic contrast-enhanced T1-weighted perfusion magnetic resonance imaging identifies glioblastoma immunohistochemical biomarkers via tumoral and peritumoral approach: A pilot study

dc.contributor.authorÖztürk, Kerem
dc.contributor.authorSoylu, Esra
dc.contributor.authorTolunay, Şahsine
dc.contributor.authorNarter, Selin
dc.contributor.authorHakyemez, Bahattin
dc.contributor.buuauthorÖzturk, Kerem
dc.contributor.buuauthorSoylu, Esra
dc.contributor.buuauthorTOLUNAY, ŞAHSİNE
dc.contributor.buuauthorNARTER, SELİN
dc.contributor.buuauthorHAKYEMEZ, BAHATTİN
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Radyoloji Anabilim Dalı.
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.
dc.contributor.orcid0000-0001-9664-2347
dc.contributor.orcid0000-0002-3425-0740
dc.contributor.researcheridAAI-2318-2021
dc.contributor.researcheridE-1228-2018
dc.contributor.researcheridAAI-1612-2021
dc.contributor.researcheridDSW-1175-2022
dc.contributor.researcheridFOL-7699-2022
dc.date.accessioned2024-07-12T06:24:52Z
dc.date.available2024-07-12T06:24:52Z
dc.date.issued2019-04-09
dc.description.abstractOBJECTIVE: We aimed to evaluate the usefulness of dynamic contrast-enhanced T1-weighted perfusion magnetic resonance imaging (DCE-pMRI) to predict certain immunohistochemical (IHC) biomarkers of glioblastoma (GB) in this pilot study.METHODS: We retrospectively reviewed 36 patients (male/female, 25:11; mean age, 53 years; age range, 29-85 years) who had pretreatment DCE-pMRI with IHC analysis of their excised GBs. Regions of interest of the enhancing tumor (ER) and nonenhancing peritumoral region (NER) were used to calculate DCE-pMRI parameters of volume transfer constant, back flux constant, volume of the extravascular extracellular space, initial area under enhancement curve, and maximum slope. IHC biomarkers including Ki-67 labeling index, epidermal growth factor receptor (EGFR), oligodendrocyte transcription factor 2 (OLIG2), isocitrate dehydrogenase 1 (IDH1), and p53 mutation status were determined. The imaging metrics of GB with IHC markers were compared using the Kruskal-Wallis test and Spearman correlation analysis.RESULTS: Among 30 patients with available IDH1 status, 14 patients (46.6%) had IDH1 mutation. EGFR amplification was present in 24/36 (66.6%) patients. Mean Ki-67 labeling index was 29% (range, 1.5%-80%). p53 mutation was present in 20/36 GBs (55%), whereas OLIG2 expression was positive in 29/36 GBs (80.5%). Various DCE-pMRI parameters gathered from the ER and NER were significantly correlated with IDH1 mutation, EGFR amplification, and OLIG2 expression (P < 0.05). Ki-67 labeling index showed a strong positive correlation with initial area under enhancement curve (r = 0.619; P < 0.001).CONCLUSIONS: DCE-pMRI could determine surrogate IHC biomarkers in GB via tumoral and peritumoral approach, potential targets for individualized treatment protocols.
dc.identifier.doi10.1016/j.wneu.2019.04.089
dc.identifier.endpageE208
dc.identifier.issn1878-8750
dc.identifier.startpageE195
dc.identifier.urihttps://doi.org/10.1016/j.wneu.2019.04.089
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S1878875019310812
dc.identifier.urihttps://hdl.handle.net/11452/43219
dc.identifier.volume128
dc.identifier.wos000475895100022
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherElsevier Science
dc.relation.journalWorld Neurosurgery
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectMicrovascular permeability
dc.subjectGenomic biomarkers
dc.subjectHistogram analysis
dc.subjectMutation status
dc.subjectMr
dc.subjectGlioma
dc.subjectParameters
dc.subjectDifferentiation
dc.subjectLymphoma
dc.subjectSurvival
dc.subjectDynamic contrast-enhanced t1-weighted perfusion mr imaging (dce-pmri)
dc.subjectEpidermal growth factor receptor (EGFR)
dc.subjectGlioblastoma (GB)
dc.subjectIsocitrate dehydrogenase 1 (IDH1)
dc.subjectOligodendrocyte transcription factor 2 (OLIG2)
dc.subjectNeurosciences & neurology
dc.subjectSurgery
dc.titleDynamic contrast-enhanced T1-weighted perfusion magnetic resonance imaging identifies glioblastoma immunohistochemical biomarkers via tumoral and peritumoral approach: A pilot study
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublication13dc6562-e9fe-42fa-8973-dcd80444844e
relation.isAuthorOfPublicationd0f32b74-f424-4145-b555-18eb0cdfb10a
relation.isAuthorOfPublication9ad8c0f1-5154-4a82-b029-77c58cb35066
relation.isAuthorOfPublication.latestForDiscovery13dc6562-e9fe-42fa-8973-dcd80444844e

Files

Collections